Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir

The best way to suppress viral replication in chronic hepatitis B remains an open question. In this 52-week open-label trial, 135 adults with hepatitis B e antigen–positive chronic hepatitis were r...

[1]  J. Pawlotsky,et al.  Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. , 2007, Journal of hepatology.

[2]  A. Cross,et al.  [49] ENTECAVIR (ETV) RESULTS IN HIGHER HBV-DNA REDUCTION VS ADEFOVIR (ADV) IN CHRONICALLY INFECTED HBeAg(+) ANTIVIRAL-NAIVE ADULTS: 48 WK RESULTS (E.A.R.L. STUDY) , 2007 .

[3]  J. Sung,et al.  Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B , 2007, Alimentary pharmacology & therapeutics.

[4]  J. Hoofnagle,et al.  Management of hepatitis B: Summary of a clinical research workshop , 2007, Hepatology.

[5]  G. Macdonald,et al.  Why do we not yet have combination chemotherapy for chronic hepatitis B? , 2007, The Medical journal of Australia.

[6]  D. Dieterich,et al.  Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen , 2006, European journal of gastroenterology & hepatology.

[7]  U. Iloeje,et al.  Past HBV Viral Load as Predictor of Mortality and Morbidity from HCC and Chronic Liver Disease in a Prospective Study , 2006, The American Journal of Gastroenterology.

[8]  T. Berg,et al.  Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy , 2006, Hepatology.

[9]  A. Cross,et al.  Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. , 2006, Gastroenterology.

[10]  C. Chapron,et al.  514 HBV resistance determination from the telbivudine globe registration trial , 2006 .

[11]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[12]  A. Lok,et al.  Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005 , 2006, Hepatology.

[13]  J. Marrero,et al.  Virologic response and resistance to adefovir in patients with chronic hepatitis B. , 2006, Journal of hepatology.

[14]  S. Zeuzem,et al.  Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients , 2006 .

[15]  A. Bisceglie,et al.  Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine , 2006 .

[16]  N. Leung,et al.  A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.

[17]  Y. Liaw,et al.  Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) , 2005 .

[18]  Y. Liaw,et al.  Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial , 2005 .

[19]  T. Berg,et al.  Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection , 2004, Hepatology.

[20]  E. Keeffe,et al.  Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.

[21]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[22]  F. Rousseau,et al.  Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature , 2003, Hepatology.

[23]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[25]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[26]  J. Petersen,et al.  Correlation of hepatitis B virus load with loss of e antigen and emerging drug‐resistant variants during lamivudine therapy , 2001, Journal of medical virology.

[27]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[28]  R. Schinazi,et al.  Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection , 2001, Antimicrobial Agents and Chemotherapy.

[29]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[30]  S. Locarnini,et al.  In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir , 2000, Antimicrobial Agents and Chemotherapy.

[31]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[32]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.